PortfoliosLab logoPortfoliosLab logo
QURE vs. SKYE
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

QURE vs. SKYE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in uniQure N.V. (QURE) and Skye Bioscience, Inc (SKYE). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, QURE achieves a 12.83% return, which is significantly higher than SKYE's 2.71% return. Over the past 10 years, QURE has outperformed SKYE with an annualized return of 8.62%, while SKYE has yielded a comparatively lower -40.24% annualized return.


QURE

1D
2.08%
1M
-2.39%
YTD
12.83%
6M
24.02%
1Y
56.34%
3Y*
11.25%
5Y*
-5.87%
10Y*
8.62%

SKYE

1D
5.02%
1M
-10.75%
YTD
2.71%
6M
-36.36%
1Y
-68.31%
3Y*
-41.13%
5Y*
-54.71%
10Y*
-40.24%
*Multi-year figures are annualized to reflect compound growth (CAGR)

QURE vs. SKYE - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
QURE
uniQure N.V.
12.83%35.50%160.86%-70.14%9.31%-42.60%-49.58%148.65%47.12%249.82%
SKYE
Skye Bioscience, Inc
2.71%-73.51%4.04%-32.84%-68.85%30.00%-69.47%-67.25%163.16%-49.67%

Correlation

The correlation between QURE and SKYE is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.19

Correlation (3Y)
Calculated over the trailing 3-year period

0.12

Correlation (5Y)
Calculated over the trailing 5-year period

0.09

Correlation (10Y)
Calculated over the trailing 10-year period

0.07

Correlation (All Time)
Calculated using the full available price history since Apr 6, 2015

0.07

The correlation between QURE and SKYE shifts across timeframes, from 0.07 (10 years) to 0.19 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

QURE:

$1.69B

SKYE:

$30.55M

EPS

QURE:

-$3.58

SKYE:

-$1.45

PB Ratio

QURE:

11.34

SKYE:

3.39

Total Revenue (TTM)

QURE:

$18.09M

SKYE:

$0.00

Gross Profit (TTM)

QURE:

$13.42M

SKYE:

-$180.01K

EBITDA (TTM)

QURE:

-$164.53M

SKYE:

$10.92M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

QURE vs. SKYE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

QURE
QURE Risk / Return Rank: 6868
Overall Rank
QURE Sharpe Ratio Rank: 5050
Sharpe Ratio Rank
QURE Sortino Ratio Rank: 8888
Sortino Ratio Rank
QURE Omega Ratio Rank: 9090
Omega Ratio Rank
QURE Calmar Ratio Rank: 5757
Calmar Ratio Rank
QURE Martin Ratio Rank: 5454
Martin Ratio Rank

SKYE
SKYE Risk / Return Rank: 1919
Overall Rank
SKYE Sharpe Ratio Rank: 1616
Sharpe Ratio Rank
SKYE Sortino Ratio Rank: 2222
Sortino Ratio Rank
SKYE Omega Ratio Rank: 2121
Omega Ratio Rank
SKYE Calmar Ratio Rank: 1212
Calmar Ratio Rank
SKYE Martin Ratio Rank: 2121
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

QURE vs. SKYE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for uniQure N.V. (QURE) and Skye Bioscience, Inc (SKYE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


QURESKYEDifference
Sharpe ratioReturn per unit of total volatility

+0.80

Sortino ratioReturn per unit of downside risk

+3.31

Omega ratioGain probability vs. loss probability

1.43

0.94

+0.49

Calmar ratioReturn relative to maximum drawdown

0.65

-0.78

+1.43

Martin ratioReturn relative to average drawdown

1.06

-1.04

+2.10

QURE vs. SKYE - Sharpe Ratio Comparison

The current QURE Sharpe Ratio is 0.21, which is higher than the SKYE Sharpe Ratio of -0.59. The chart below compares the historical Sharpe Ratios of QURE and SKYE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


QURESKYEDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.21

-0.59

+0.80

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.04

-0.42

+0.38

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.07

-0.29

+0.37

Sharpe Ratio (All Time)

Calculated using the full available price history

0.05

-0.36

+0.40

Drawdowns

QURE vs. SKYE - Drawdown Comparison

The maximum QURE drawdown since its inception was -95.40%, roughly equal to the maximum SKYE drawdown of -99.96%. Use the drawdown chart below to compare losses from any high point for QURE and SKYE.


Loading charts...

Drawdown Indicators


QURESKYEDifference

Max Drawdown

Largest peak-to-trough decline

-95.40%

-99.96%

+4.56%

Max Drawdown (1Y)

Largest decline over 1 year

-87.21%

-87.85%

+0.64%

Max Drawdown (3Y)

Largest decline over 3 years

-87.21%

-96.79%

+9.58%

Max Drawdown (5Y)

Largest decline over 5 years

-90.11%

-98.66%

+8.55%

Max Drawdown (10Y)

Largest decline over 10 years

-95.40%

-99.83%

+4.43%

Current Drawdown

Current decline from peak

-67.15%

-99.94%

+32.79%

Average Drawdown

Average peak-to-trough decline

-56.58%

-94.95%

+38.37%

Ulcer Index

Depth and duration of drawdowns from previous peaks

53.50%

65.76%

-12.26%

Volatility

QURE vs. SKYE - Volatility Comparison

uniQure N.V. (QURE) and Skye Bioscience, Inc (SKYE) have volatilities of 28.01% and 28.64%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


QURESKYEDifference

Volatility (1M)

Calculated over the trailing 1-month period

28.01%

28.64%

-0.63%

Volatility (6M)

Calculated over the trailing 6-month period

92.44%

63.38%

+29.06%

Volatility (1Y)

Calculated over the trailing 1-year period

273.61%

115.33%

+158.28%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

154.08%

130.81%

+23.27%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

119.92%

137.31%

-17.39%

Dividends

QURE vs. SKYE - Dividend Comparison

Neither QURE nor SKYE has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

QURE vs. SKYE - Financials Comparison

This section allows you to compare key financial metrics between uniQure N.V. and Skye Bioscience, Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00100.00M200.00M300.00M400.00M500.00M20222023202420252026
3.56M
0
(QURE) Total Revenue
(SKYE) Total Revenue
Values in USD except per share items

Frequently Asked Questions


QURE and SKYE have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

SKYE has higher volatility (28.64%) compared to QURE (28.01%). In terms of maximum drawdown, QURE dropped -95.40% vs SKYE's -99.96%.

QURE currently has the higher Sharpe Ratio (0.21 vs -0.59), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for QURE and SKYE

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer